Trials (Mar 2023)

Leukocyte- and platelet-rich fibrin in cranial surgery: study protocol for a prospective, parallel-group, single-blinded randomized controlled non-inferiority trial {1}

  • Birgit Coucke,
  • Anaïs Van Hoylandt,
  • Johannes van Loon,
  • Frank Van Calenbergh,
  • Laura Van Gerven,
  • Tom Theys

DOI
https://doi.org/10.1186/s13063-023-07252-w
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background CSF leakage is a major complication after cranial surgery, thus, adequate dural closure must be performed. Commercially available fibrin sealants are currently considered the gold standard for dural closure, but problems have been reported regarding safety, efficacy, and costs. This trial aims to investigate autologous leukocyte- and platelet-rich fibrin (L-PRF) as an alternative to commercially available fibrin sealants. Methods/design This single-blinded, prospective randomized controlled interventional trial aims to demonstrate the non-inferiority of L-PRF compared to commercially available fibrin sealants for dural closure. This trial will include patients undergoing cranial neurosurgery (supratentorial and infratentorial) with intentional opening of the dura. Patients are randomized in a 1:1 fashion comparing L-PRF to commercially available fibrin sealants. The primary endpoint is postoperative CSF leakage within 12 weeks after surgery. Secondary endpoints are complications such as bleeding or wound infections. Additionally, a cost-effectiveness analysis is performed. Discussion With this trial, we will evaluate the safety and efficiency of L-PRF compared to commercially available fibrin sealants. Trial registration ClinicalTrials.gov NCT03812120. Registered on 22 January 2019.

Keywords